Document Detail

Covered versus uncovered self-expandable nitinol stents in the palliative treatment of malignant distal biliary obstruction: results from a randomized, multicenter study.
MedLine Citation:
PMID:  21034892     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Covered biliary metal stents have been developed to prevent tumor ingrowth. Previous comparative studies are limited and often include few patients.
OBJECTIVE: To compare differences in stent patency, patient survival, and complication rates between covered and uncovered nitinol stents in patients with malignant biliary obstruction.
DESIGN: Randomized, multicenter trial conducted between January 2006 and October 2008.
SETTING: Ten sites serving a total catchment area of approximately 2.8 million inhabitants.
PATIENTS: A total of 400 patients with unresectable distal malignant biliary obstruction.
INTERVENTIONS: ERCP with insertion of covered or uncovered metal stent. Follow-up conducted monthly for symptoms indicating stent obstruction.
MAIN OUTCOME MEASUREMENTS: Time to stent failure, survival time, and complication rate.
RESULTS: The patient survival times were 116 days (interquartile range 242 days) and 174 days (interquartile range 284 days) in the covered and uncovered stent groups, respectively (P = .320). The first quartile stent patency time was 154 days in the covered stent group and 199 days in the uncovered stent group (P = .326). There was no difference in the incidence of pancreatitis or cholecystitis between the 2 groups. Stent migration occurred in 6 patients (3%) in the covered group and in no patients in the uncovered group (P = .030).
LIMITATIONS: Randomization was not blinded.
CONCLUSIONS: There were no significant differences in stent patency time, patient survival time, or complication rates between covered and uncovered nitinol metal stents in the palliative treatment of malignant distal biliary obstruction. However, covered stents migrated significantly more often compared with uncovered stents, and tumor ingrowth was more frequent in uncovered stents.
Eric Kullman; Farshad Frozanpor; Claes Söderlund; Stefan Linder; Per Sandström; Anna Lindhoff-Larsson; Ervin Toth; Gert Lindell; Eduard Jonas; Jacob Freedman; Martin Ljungman; Claes Rudberg; Bo Ohlin; Rebecka Zacharias; Carl-Eric Leijonmarck; Kalev Teder; Anders Ringman; Gunnar Persson; Mehmet Gözen; Olle Eriksson
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Gastrointestinal endoscopy     Volume:  72     ISSN:  1097-6779     ISO Abbreviation:  Gastrointest. Endosc.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-11-01     Completed Date:  2011-04-19     Revised Date:  2011-07-20    
Medline Journal Info:
Nlm Unique ID:  0010505     Medline TA:  Gastrointest Endosc     Country:  United States    
Other Details:
Languages:  eng     Pagination:  915-23     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.
University Hospital, Linköping, Sweden.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Biliary Tract Neoplasms / complications,  pathology*,  therapy
Cholangiopancreatography, Endoscopic Retrograde*
Cholestasis / etiology,  pathology,  therapy*
Cohort Studies
Disease-Free Survival
Equipment Design
Middle Aged
Palliative Care*
Treatment Outcome
Reg. No./Substance:
0/Alloys; 52013-44-2/nitinol
Comment In:
Gastrointest Endosc. 2010 Nov;72(5):924-6   [PMID:  21034893 ]
Gastrointest Endosc. 2011 Jun;73(6):1329-30; author reply 1330-1   [PMID:  21628024 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A randomized trial comparing uncovered and partially covered self-expandable metal stents in the pal...
Next Document:  Efficacy and safety of biodegradable stents for refractory benign esophageal strictures: the BEST (B...